ArticlePloS one2015
Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- A systematic review on anti-malarial drug discovery and antiplasmodial potential of green synthesis mediated metal nanoparticles: overview, challenges and future perspectives.Malaria journal · 2019Pooled it
- Biomimetic Copper Nanoparticles Coated with ACE2-Overexpressing Membranes for Selective SARS-CoV-2 Neutralization and Disinfection.Advanced healthcare materials · 2026Article
- Bio-inspired Synthesis, Characterization, and Biomedical Applications of Optimized Ceiba pentandra Silver Nanoparticles.Biological trace element research · 2025Article
- Antimicrobial activity of gentamicin-conjugated monometallic and bimetallic nanoparticles against multidrug-resistant Klebsiella pneumoniae strains.Folia microbiologica · 2025Article
- Engineering copper and copper-based materials for a post-antibiotic era.Frontiers in bioengineering and biotechnology · 2025Review
- Antiviral properties and molecular docking studies of eco-friendly biosynthesized copper oxide nanoparticles against alfalfa mosaic virus.BMC plant biology · 2024Article
- A systematic overview of metal nanoparticles as alternative disinfectants for emerging SARS-CoV-2 variants.Archives of microbiology · 2024Review
- Antifungal Activity and Molecular Mechanisms of Copper Nanoforms againstNanomaterials (Basel, Switzerland) · 2023Article
- Recent Updates on Multifunctional Nanomaterials as Antipathogens in Humans and Livestock: Classification, Application, Mode of Action, and Challenges.Molecules (Basel, Switzerland) · 2023Review
- Biosynthesis of Copper Nanoparticles with Medicinal Plants Extracts: From Extraction Methods to Applications.Micromachines · 2023Review
- An overview of SARS-CoV-2 transmission and engineering strategies to mitigate risk.Journal of building engineering · 2023Review
- Toxicity Mechanisms of Copper Nanoparticles and Copper Surfaces on Bacterial Cells and Viruses.International journal of molecular sciences · 2023Review
- Nanocellulose-Based Passivated-Carbon Quantum Dots (P-CQDs) for Antimicrobial Applications: A Practical Review.Polymers · 2023Review
- Antiviral Activity of Zinc Oxide Nanoparticles against SARS-CoV-2.International journal of molecular sciences · 2023Article
- A Novel Vision of Reinforcing Nanofibrous Masks with Metal Nanoparticles: Antiviral Mechanisms Investigation.Advanced fiber materials · 2023Review
- Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications.Pharmaceutics · 2023Review
- Tackling COVID-19 Using Antiviral Nanocoating's-Recent Progress and Future Challenges.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2023Review
- Sparking Nano-Metals on a Surface of Polyethylene Terephthalate and Its Application: Anti-Coronavirus and Anti-Fogging Properties.International journal of molecular sciences · 2022Article
- Antiviral Activity and Mechanisms of Seaweeds Bioactive Compounds on Enveloped Viruses-A Review.Marine drugs · 2022Review
- Engineered nanomaterials in plant diseases: can we combat phytopathogens?Applied microbiology and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human norovirus is a leading cause of acute gastroenteritis worldwide in a plethora of residential and commercial settings, including restaurants, schools, and hospitals. Methods for easily detecting the virus and for treating and preventing infection are critical to stopping norovirus outbreaks, and inactivation via nanoparticles (NPs) is a more universal and attractive alternative to other physical and chemical approaches. Using norovirus GI.1 (Norwalk) virus-like particles (VLPs) as a model viral system, this study characterized the antiviral activity of Au/CuS core/shell nanoparticles (NPs) against GI.1 VLPs for the rapid inactivation of HuNoV. Inactivation of VLPs (GI.1) by Au/CuS NPs evaluated using an absorbance-based ELISA indicated that treatment with 0.083 μM NPs for 10 min inactivated ~50% VLPs in a 0.37 μg/ml VLP solution and 0.83 μM NPs for 10 min completely inactivated the VLPs. Increasing nanoparticle concentration and/or VLP-NP contact time significantly increased the virucidal efficacy of Au/CuS NPs. Changes to the VLP particle morphology, size, and capsid protein were characterized using dynamic light scattering, transmission electron microscopy, and Western blot analysis. The strategy reported here provides the first reported proof-of-concept Au/CuS NPs-based virucide for rapidly inactivating human norovirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.